These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

585 related items for PubMed ID: 18762674

  • 1. A novel point-of-care assay for the monitoring of low-molecular weight heparins in the cardiac catheterization laboratory.
    Marmur JD, Lakhani M, El Rouby S, Cavusoglu E.
    J Invasive Cardiol; 2008 Sep; 20(9):449-54. PubMed ID: 18762674
    [Abstract] [Full Text] [Related]

  • 2. The activated clotting time (ACT) can be used to monitor enoxaparin and dalteparin after intravenous administration.
    Cavusoglu E, Lakhani M, Marmur JD.
    J Invasive Cardiol; 2005 Aug; 17(8):416-21. PubMed ID: 16079447
    [Abstract] [Full Text] [Related]

  • 3. Enoxaparin anticoagulation monitoring in the catheterization laboratory using a new bedside test.
    Silvain J, Beygui F, Ankri A, Bellemain-Appaix A, Pena A, Barthelemy O, Cayla G, Gallois V, Galier S, Costagliola D, Collet JP, Montalescot G.
    J Am Coll Cardiol; 2010 Feb 16; 55(7):617-25. PubMed ID: 20170785
    [Abstract] [Full Text] [Related]

  • 4. Factor Xa-activated whole blood clotting time (Xa-ACT) for bedside monitoring of dalteparin anticoagulation during haemodialysis.
    Frank RD, Brandenburg VM, Lanzmich R, Floege J.
    Nephrol Dial Transplant; 2004 Jun 16; 19(6):1552-8. PubMed ID: 15034159
    [Abstract] [Full Text] [Related]

  • 5. Avoiding intelligence failures in the cardiac catheterization laboratory: Strategies for the safe and rational use of dalteparin or enoxaparin during percutaneous coronary intervention.
    Marmur JD, Bullock-Palmer RP, Poludasu S, Cavusoglu E.
    J Invasive Cardiol; 2009 Dec 16; 21(12):653-64. PubMed ID: 19966370
    [Abstract] [Full Text] [Related]

  • 6. The use of a HEMOCHRON JR. HEMONOX point of care test in monitoring the anticoagulant effects of enoxaparin during interventional coronary procedures.
    El Rouby S, Cohen M, Gonzales A, Hoppensteadt D, Lee T, Zucker ML, Khalid K, Laduca FM, Fareed J.
    J Thromb Thrombolysis; 2006 Apr 16; 21(2):137-45. PubMed ID: 16622609
    [Abstract] [Full Text] [Related]

  • 7. Activated clotting time (ACT)-guided intravenous dalteparin dosing during percutaneous coronary intervention.
    Marmur JD, Poludasu S, Feit A, Battala VR, Cavusoglu E.
    J Invasive Cardiol; 2008 Jul 16; 20(7):323-7. PubMed ID: 18599887
    [Abstract] [Full Text] [Related]

  • 8. A randomized comparative study of using enoxaparin instead of unfractionated heparin in the intervention treatment of coronary heart disease.
    Chen JL, Chen J, Qiao SB, Guo YL, Wu YJ, Dai J, Yuan JQ, Qin XW, Yang YJ, Gao RL.
    Chin Med J (Engl); 2006 Mar 05; 119(5):355-9. PubMed ID: 16542576
    [Abstract] [Full Text] [Related]

  • 9. Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular-weight heparin?
    Henry TD, Satran D, Knox LL, Iacarella CL, Laxson DD, Antman EM.
    Am Heart J; 2001 Oct 05; 142(4):590-3. PubMed ID: 11579347
    [Abstract] [Full Text] [Related]

  • 10. A randomized pilot study of dalteparin versus unfractionated heparin during percutaneous coronary interventions.
    Natarajan MK, Velianou JL, Turpie AG, Mehta SR, Raco D, Goodhart DM, Afzal R, Ginsberg JS.
    Am Heart J; 2006 Jan 05; 151(1):175. PubMed ID: 16368313
    [Abstract] [Full Text] [Related]

  • 11. Early ambulation and variability in anticoagulation during elective coronary stenting with a single intravenous bolus of low-dose, low-molecular weight heparin enoxaparin.
    Zalc S, Lemos PA, Esteves A, Ribeiro EE, Horta P, Nicolau JC, Ramires JA, Cohen M, Martinez EE.
    J Invasive Cardiol; 2006 Feb 05; 18(2):45-8. PubMed ID: 16446514
    [Abstract] [Full Text] [Related]

  • 12. Stable and optimal anticoagulation is achieved with a single dose of intravenous enoxaparin in patients undergoing percutaneous coronary intervention.
    Chen WH, Lau CP, Lau YK, Ng W, Lee PY, Yu CM, Ma E.
    J Invasive Cardiol; 2002 Aug 05; 14(8):439-42. PubMed ID: 12147872
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions.
    Aslam MS, Sundberg S, Sabri MN, Cooke D, Lakier JB.
    Catheter Cardiovasc Interv; 2002 Oct 05; 57(2):187-90. PubMed ID: 12357518
    [Abstract] [Full Text] [Related]

  • 14. The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration.
    Marmur JD, Anand SX, Bagga RS, Fareed J, Pan CM, Sharma SK, Richard MF.
    J Am Coll Cardiol; 2003 Feb 05; 41(3):394-402. PubMed ID: 12575965
    [Abstract] [Full Text] [Related]

  • 15. Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
    Ellison J, Thomson AJ, Conkie JA, McCall F, Walker D, Greer A.
    Thromb Haemost; 2001 Dec 05; 86(6):1374-8. PubMed ID: 11776302
    [Abstract] [Full Text] [Related]

  • 16. [The assessment of safety of enoxaparin administration during percutaneous transluminal coronary angioplasty after ticlopidine pretreatment. Application of low molecular weigh heparins in prevention of coronary micro-embolization].
    Dudek D, Zymek P, Bartuś S, Dubiel JS.
    Przegl Lek; 2001 Dec 05; 58(6):484-6. PubMed ID: 11816736
    [Abstract] [Full Text] [Related]

  • 17. Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals.
    Oldgren J, Johnston N, Siegbahn A.
    Am Heart J; 2008 Mar 05; 155(3):493.e1-8. PubMed ID: 18294482
    [Abstract] [Full Text] [Related]

  • 18. Anticoagulation monitoring part 2: Unfractionated heparin and low-molecular-weight heparin.
    Spinler SA, Wittkowsky AK, Nutescu EA, Smythe MA.
    Ann Pharmacother; 2005 Mar 05; 39(7-8):1275-85. PubMed ID: 15956240
    [Abstract] [Full Text] [Related]

  • 19. Adding intravenous unfractionated heparin to standard enoxaparin causes excessive anticoagulation not detected by activated clotting time: results of the STACK-on to ENOXaparin (STACKENOX) study.
    Drouet L, Bal dit Sollier C, Martin J.
    Am Heart J; 2009 Aug 05; 158(2):177-84. PubMed ID: 19619692
    [Abstract] [Full Text] [Related]

  • 20. High plasma endostatin level unaffected by low-molecular weight heparin in hemodialysis patients--a preliminary report.
    Rydzewska-Rosolowska A, Borawski J, Mysliwiec M.
    Adv Med Sci; 2009 Aug 05; 54(2):199-202. PubMed ID: 19758969
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.